Xian He
About Xian He
Xian He serves as the Senior Director of Biostatistics at Arcus Biosciences, where he has worked since 2020. He previously held the position of Principal Statistical Scientist at Genentech and has significant experience in biostatistics, particularly in leading studies for the drug Tecentriq.
Work at Arcus Biosciences
Xian He has been serving as the Senior Director of Biostatistics at Arcus Biosciences since 2020. In this role, he leads biostatistical initiatives and contributes to the development of high-quality data packages for business development meetings. His responsibilities include representing biometrics and ensuring the integrity of statistical analyses in clinical trials.
Previous Experience at Genentech
Prior to joining Arcus Biosciences, Xian He worked at Genentech as a Principal Statistical Scientist from 2015 to 2020. During his tenure in South San Francisco, he served as the international biostat lead for Tecentriq indications, focusing on significant phase III studies such as IMpower150, IMpower133, and IMpower130.
Education and Expertise
Xian He earned his Doctor of Philosophy (PhD) in Statistics from Purdue University, where he studied from 2009 to 2014. He also holds a Master of Science (M.S.) in Statistics from the same institution, completing his studies from 2009 to 2012. His expertise includes complex randomized basket and umbrella trial designs, protocol writing, and IND clearance processes.
Experience at Bristol-Myers Squibb
Xian He began his career with an internship as a Statistician at Bristol-Myers Squibb in 2014, where he worked for three months in the Greater New York City Area. This role provided him with foundational experience in the biostatistics field.
Achievements in Business Development
In his role at Arcus Biosciences, Xian He has led the biometrics effort in due diligence for business development. His work has directly contributed to the opt-in and co-development of multiple programs with companies such as Gilead and AstraZeneca. He has also played a significant role in addressing health authority questions, facilitating the approval of Tecentriq in various international markets.